Episode Details
Back to Episodes
1.22 Elo-Pom-Dex, Immunotherapy Combos, Inherent Bias, and the FDA with Dr. Erick Turner
Published 7 years, 9 months ago
Description
In this episode, we tackle the recent papers in the New England Journal of Medicine on "Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma" and "Immunotherapy Combinations in Multiple Myeloma", as well as a comment in The Lancet Oncology's editorial "9 Weeks That Matter for Patients With Gastric Cancer". We conclude with an interview with Dr. Erick Turner of OHSU on the FDA, regulatory capture, selective reporting, and transparency.
Elo-pom-dex: http://doi.org/10.1056/NEJMoa1805762
Immunotherapy combinations: http://doi.org/10.1056/NEJMp1803602
9 weeks that matter: http://doi.org/10.1016/S1470-2045(18)30752-6
Dr. Turner's seminal paper: https://doi.org/10.1056/NEJMsa065779